CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 95 enrolled
Drug / intervention
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets +1 moredrug
Likely dose
Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets, 1 tablet daily by mouthAI-extracted
Key inclusion· 3
  • Sexually naïve and agree to abstain from sex during the study
  • Moderate to severe menstrual-related pelvic pain
  • Regular spontaneous menstrual cycles
Key exclusion· 3
  • Any contraindication to the use of oral contraceptives
  • Treatment with an oral contraceptive within the previous 3 months
  • Previous treatment failure with an extended oral contraceptive regimen

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00196313
NCT00196313Phase 2Completed

A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents

Duramed Research·interventional·Posted Sep 20, 2005·Updated Sep 22, 2016

In Brief

A Phase 2 clinical trial evaluating levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets and Placebo tablet for Dysmenorrhea. Completed, enrolled 95 participants across 13 sites.

Detailed Summary

This study is being conducted to evaluate the effects of treatment with Seasonique an extended-regimen oral contraceptive that utilizes low dose ethinyl estradiol during the typical hormone-free interval. Patients will receive 13 weeks of treatment with the option to extend blinded therapy for an additional 13 weeks. The overall study duration will be 6-9 months. Patients will be required to record menstrual pain in a daily diary.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDysmenorrhea
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 20, 2005
Enrollment StartMay 1, 2005
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 20.8 years ago

Interventions

levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tabletsdrug

1 tablet daily by mouth

Placebo tabletdrug

1 tablet daily by mouth